In US adults with diabetes in a claims database, acute pancreatitis incidence with liraglutide (187.5 per 100,000 person-years) did not differ significantly from non-GLP-1-based therapies (154.4; adjusted RR 1.10).
In plain wordsIn US insurance data, people using liraglutide did not have a clearly higher rate of acute pancreatitis than people using other non-GLP-1 diabetes drugs.
- Peptide
- Liraglutide
- Outcome
- No significant changeAcute pancreatitis
- Study
n: not reported in source
- Comparator
- All non-GLP-1-based therapies
- Outcome group
- Adverse events · Gastrointestinal
- Studied dose
- Dose not stated
Measurements
- Incidence rate
- 187.5 per 100 000 person-years
- liraglutide
- Incidence rate
- 154.4 per 100 000 person-years
- non-GLP-1-based therapies
- Adjusted rate ratio
- 1.1
- 95% CI 0.81-1.49
Source sentences
The IR for acute pancreatitis for liraglutide was 187.5 compared with 154.4 for all non-glucagon-like peptide-1 (GLP-1)-based therapies (adjusted RR 1.10; CI 0.81-1.49).
1 context sentence(design, population, supporting numbers)
Initiators of liraglutide, exenatide, metformin, pioglitazone or groups containing initiators of dipeptidyl peptidase-4 inhibitors or sulfonylureas were identified in a US commercial health insurance claims database (1 February 2010 to 31 March 2013) and followed for a median of 15 months.